Early Increase of chondroitin sulfate glycosaminoglycan in the glomerular basement membrane of rats with diabetic glomerulopathy

Nephron

Volumn 76, Issue 1, 1997, Pages 62-71

  Karasawa, R ^a   Nishi, S ^a   Suzuki, Y ^a   Imai, N ^a   Arakawa, M ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Cationic colloidal gold; Chondroitin sulfate glycosaminoglycan; Glomerular basement membrane; Heparan sulfate glycosaminoglycan; Polyethyleneimine; WBN Kob rat

Indexed keywords

CHONDROITIN; GLYCOSAMINOGLYCAN POLYSULFATE; GOLD 198; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULUS BASEMENT MEMBRANE; MEMBRANE STRUCTURE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030987814     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000190142     Document Type: Article

References (34)

1. Makino H., Yamasaki Y., Haramolo T., Shikata K., Hironaka K., Ota Z., Kanwar YS: Ultrastruc-tural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelcctron microscopy., Lab Invest 1993;68:45-55.
2. Moriva T., Olino S., Nakazaxva K., Shigematsu H., Yajima Y: Ultrastructural study of glomerular basement membrane in diabetic rats by quick-freezing and deep-etching method., Virchows Arch B Cell Pathol 1993;64:107-114.
3. Rohrbach R: Reduced content and abnormal distribution of anionic sites (acid proteoglycans) in the diabetic glomerular basement membrane., Virchows Arch B Cell Pathol 1986: 51:127-135.
4. Vernier RL., Sleffes MW, Sisson-Ross S., Maucr SM: Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus., Kidney Int 1992:41:1070-1080.
5. Chakrabarti S., Ma N., Sima AAF: Reduced number of anionic sites is associated with glomerular basement membrane thickening in the diabetic BB-rat., Diabctologia 1989:32:826-828.
6. Morikawa A, Eto M., Makino I: The effect of dilazep on urinary protein excretion in spontaneous diabetic Chinese hamster., Nephron 1993;65:125-132.
7. Deckert T., Feldt-Rasmussen B., Djurup R., Deckcrt M: Glomerular size and charge selectivity in insulin-dependent diabetes mellitus., Kidney Int 1988:33:100-106.
8. Pictravalle P., Morano S., Cristina G., Rossi MG., Mariani G., Cotronco P., Ghirlanda G., Clementi A, Andreani D, Mario U: Charge selectivity of proteinuria in type I diabetes explored by Ig subclass clearance., Diabetes 1991:40:1685-1690.
9. Nerlich A., Schleicher E: Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions., Am J Pathol 1991;139:889-899.
10. Tamsma JT., Born J., Bruijn JA., Assmann KJM., Weening JJ., Bcrden JHM., Wicslander J., Schra-ma E., Hermans J, Veerkamp JH, Lemkes HHPJ, Woude FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulfate in the glomerular basement membrane., Diabe-tologia 1994;37:313-320.
11. Kanwar YS., Hascall VC., Farquhar MG: Partial characterization of newly synthesized proteoglycans isolated from the glomerular basement membrane., J Cell Biol 1981:90:527-532.
12. Kanwar YS., Rosenzweig U., Jakubowski ML: Distribution of de novo synthesized sulfated glycosaminoglycans in the glomerular basement membrane and mesangial matrix., Lab Invest 1983:49:216-225.
13. Couchman JR., Abrahamson DR., McCarthy KJ: Basement membrane proteoglycans and development., Kidney Int 1993:43:79-84.
14. Goode NP, Shires M., Crcllin DM, Davison AM: Detection of glomerular anionic sites in post-embedded ultra-thin sections using cationic colloidal gold., J Histochcm Cytochcm 1991:39:965-972.
15. Mori Y., Yokohama J., Nishimura M., Kurata H., Miura J., Ikcda Y: Diabetic strain (WBN/Kob) of rat characterized by endocrine-exocrine pancreatic impairment due to distinct fibrosis., Pancreas 1990:5:452-459.
16. Tsuchitani M., Saegusa T., Narama J., Nishitani T., Gonda T: A new diabetic strain of rat (WBN/Kob)., Lab Anim 1985;19:200-207.
17. Nakama K., Shichinohc K, Kobayashi K, Naito K., Lchida O, Yasuhara K., Tobc M: Spontaneous diabetes-like syndrome in WBN/Kob rats., Acta Diabetol Lat 1985:22:335-342.
18. Mori Y, Yokoyama J., Nishimura M., Oka H., Mochio S, Ikeda Y: Development of diabetic complications in a new diabetic strain of rat (WBN/Kob)., Pancreas 1992;7:569-577.
19. Ishizaki M, Masuda Y., Fukuda Y., Yamanaka N., Masugi Y., Shichinohe K., Nakama K: Renal lesions in a strain of spontaneously diabetic WBN/Kob rats., Acta Diabetol Lat 1987;24:27-35.
20. Tagc Y., Katsuta O, Tsuchitani M, Narama I., Itakura C: Glomerular lesions in spontaneously occurring diabetic WBN/Kob rats., J Comp Pathol 1991:104:367-377.
21. Yagihashi S., Wada R., Kamijo M., Nagai K: Peripheral neuropathy in the WBN/Kob rat with chronic pancreatitis and spontaneous diabetes., Lab Invest 1993:68:296-307.
22. Nishi S., Ozawa H, Arakawa M: A cvtochemical study of glycocalvx and the membrane cholesterol of rat glomerular podocytes., Arch Histol Cytol 1990;53:371-379.
23. Schurer JW, Kalicharan D., J locdcmaeker PI IJ., Molenaar I: The use of polycthyleneiminc for demonstration of anionic sites in basement membranes and collagen fibrils., J Histochem Cytochcm 1978:26:688-689.
24. Goode NP., Shires M, Aparicio SR., Davison AM: Cationic colloidal gold-A novel marker for the demonstration of glomerular polvanion status in routine renal biopsies., Nephrol Dial Transplant 1991:6:923-930.
25. Kurc S, Yoshie O: A syngeneic monoclonal antibody to murine Meth-A sarcoma (I-lepSS-I) recognizes heparan sulfate glycosaminogly-can (HS-GAG): Cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1., J Immunol 1986: 137:3900-3908.
26. Yamagata M., Kimata K., Oike Y., Tani K., Mac-da N., Yoshida K, Shimomura Y., Yoneda M., Suzuki S: A monoclonal antibody that specifically recognizes a glucuronic acid 2-sulfate-containing determinant in intact chondroitin sulfate chain., J BiolChcm 1987:262:4146-4152.
27. Vernier RL., Klein DJ., Sisson SP., Mahan JD., Ocgcma TR., Brown DM: Heparan sulfate-rich anionic sites in the human glomerular basement membrane: Decreased concentration in congenital nephrotic syndrome., N Engl J Med 1983:309:1001-1009.
28. Rosenzwcig U., Kanwar YS: Removal of sul-fated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to ’-’l-bovinescrum albumin., Lab Invest 1982:47:177-184.
29. Bcrtolalus JA., Hunsickcr LG: Polycation binding to glomerular basement: Effect of biochemical modification., Lab Invest 1987:56:170-179.
30. Goode NP., Shires M., Crellin DM., Aparicio SR., Davison AM: Alterations of glomerular basement membrane charge and structure in diabetic nephropathy., Diabetologia 1995:38: 1455-1465.
31. Michels LD., Davidman M., Keane WF: Glomerular permeability to neutral and anionic dextrans in experimental diabetes., Kidnev Int 1982:21:699-705.
32. McCarthy KJ, Abrahamson DR., Bynum KR., St John PL, Couchman JR: Basement membrane-specific chondroitin sulfate proteoglycan is abnormally associated with the glomerular capillary basement membrane of diabetic rats., J Histochem Cytochem 1994:42:473-484.
33. Yamamoto T., Nakamura T., Noble NA., Ruos-lahti E., Border WA: Expression of transforming growth factor 5 is elevated in human and experimental diabetic glomerulopathy., Proc Natl Acad Sci USA 1993:90:1814-1818.
34. Border WA, Noble NA, Yamamoto T., Harper JR., Yamaguchi Y, Pierschbacher MD., Ruos-lahti E: Natural inhibitor of transforming growth factor-p protects against scarring in experimental kidney disease., Nature 1992:360: 361-364